Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalba Mansi

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 6, 2024
Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapyLuigi Aloj, Rosalba Mansi, Stefania De Luca, et al.
EJNMMI Research|August 7, 2020
A new <sup>68</sup>Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targetingRosalba Mansi, Karim Abid, Guillaume P Nicolas, et al.
Molecular Biosystems|June 20, 2012
Activation of monocytic cells by immunostimulatory lipids conjugated to peptide antigensStefania Galdiero, Mariateresa Vitiello, Emiliana Finamore, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 29, 2017
Biodistribution, Pharmacokinetics, and Dosimetry of <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>111</sup>In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist <sup>177</sup>Lu-DOTATATE: The Mass EffectGuillaume P Nicolas, Rosalba Mansi, Lisa McDougall, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2023
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptidesJacopo Millul, Lennart Koepke, Gaonkar Raghuvir Haridas, et al.
Chemmedchem|January 9, 2025
Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4Raghuvir H Gaonkar, Thibaud Bailly, Jacopo Millul, et al.
Biomaterials|April 18, 2013
Multifactorial diagnostic NIR imaging of CCK2R expressing tumorsSusanne Kossatz, Martin Béhé, Rosalba Mansi, et al.
Molecules (Basel, Switzerland)|September 16, 2020
Evaluation of a New <sup>177</sup>Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, et al.
EJNMMI Radiopharmacy and Chemistry|July 1, 2025
Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitutionRosalba Mansi, Natalie Bertarelli, Luigi Del Pozzo, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive TumoursPascale Plas, Lorenzo Limana, Denis Carré, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 6, 2024
Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapyLuigi Aloj, Rosalba Mansi, Stefania De Luca, et al.
EJNMMI Research|August 7, 2020
A new <sup>68</sup>Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targetingRosalba Mansi, Karim Abid, Guillaume P Nicolas, et al.
Molecular Biosystems|June 20, 2012
Activation of monocytic cells by immunostimulatory lipids conjugated to peptide antigensStefania Galdiero, Mariateresa Vitiello, Emiliana Finamore, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 29, 2017
Biodistribution, Pharmacokinetics, and Dosimetry of <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>111</sup>In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist <sup>177</sup>Lu-DOTATATE: The Mass EffectGuillaume P Nicolas, Rosalba Mansi, Lisa McDougall, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2023
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptidesJacopo Millul, Lennart Koepke, Gaonkar Raghuvir Haridas, et al.
Chemmedchem|January 9, 2025
Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4Raghuvir H Gaonkar, Thibaud Bailly, Jacopo Millul, et al.
Biomaterials|April 18, 2013
Multifactorial diagnostic NIR imaging of CCK2R expressing tumorsSusanne Kossatz, Martin Béhé, Rosalba Mansi, et al.
Molecules (Basel, Switzerland)|September 16, 2020
Evaluation of a New <sup>177</sup>Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, et al.
EJNMMI Radiopharmacy and Chemistry|July 1, 2025
Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitutionRosalba Mansi, Natalie Bertarelli, Luigi Del Pozzo, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive TumoursPascale Plas, Lorenzo Limana, Denis Carré, et al.
Pageof 6